Nifedipine effect on red cell rheological properties in patients with systemic scleroderma

Clinical Hemorheology and Microcirculation

Volumn 36, Issue 2, 2007, Pages 105-110

  Spengler, M I ^a   Leroux, M B ^b   Svetaz, M J ^a   Contesti, J F ^a   Parente, F M ^a   Bertoluzzo, S M ^a  

^a UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

^b FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

Author keywords

Erythrocyte deformability; Membrane erythrocyte fluidity; Nifedipine; Osmotic fragility; Systemic scleroderma

Indexed keywords

CALCIUM; COLCHICINE; NIFEDIPINE;

ADULT; ARTICLE; BLOOD RHEOLOGY; CELL MEMBRANE FLUIDITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; ERYTHROCYTE; ERYTHROCYTE DEFORMABILITY; ERYTHROCYTE FRAGILITY; ERYTHROCYTE MEMBRANE; FEMALE; HUMAN; SYSTEMIC SCLEROSIS;

ADULT; BLOOD VISCOSITY; CALCIUM CHANNEL BLOCKERS; ERYTHROCYTE DEFORMABILITY; FEMALE; HEMORHEOLOGY; HUMANS; NIFEDIPINE; OSMOTIC FRAGILITY; SCLERODERMA, SYSTEMIC;

EID: 33847323046     PISSN: 13860291     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. J.J. Belch, M. Mc Laren, J. Anderson, G.D. Lowe, R.D. Sturrock, H.A. Capell and C.D. Forbes, Increased prostacyclin metabolites and decreased red cells deformability in patients with systemic sclerosis and Raynaud's syndrome, Prostaglandins Leukot. Med. 17(1) (1985), 1-9.
2. J.J. Belch, Raynaud's phenomenon, Cur. Op. Rheumatol. 1 (1989), 490-498.
3. M. Bor-Kucukatay, H.J. Meiselman and O.K. Baskurt, Modulation of density-fractionated RBC deformability by nitric oxide, Clin. Hemorheol. Microcirc. 33 (2005), 363-367.
4. C. Bruneau, D. Laustriat, V. Camberlein, G. Crmel and M.L. North, Effects of two cholesterol derivatives on erythrocyte deformability and membrane fluidity on intact red blood cells and ghosts, Clin. Hemorheol. 11 (1991), 583-595.
5. E. Brzezinska-Slebodzinska, Erythrocyte osmotic fragility test as measure of defence against free radicals in rabbits of different age, Acta Vet. Hung. 49(4) (2001), 413-419.
6. G. Caimi, A. Serra, A. Catania, S. D'Asaro, R. Lo Presti and A. Sarno, Microrheological determinants and erythrocytes membrane phospholipids in vascular atherosclerotic disease (VAD), Clin. Hemorheol. 10 (1990), 449-458.
7. M.R. Clark, N. Mohandas, C. Feo, M.S. Jacobs and S.B. Shohet, Separate mechanisms of deformability loss in ATP-depleted and Ca-loaded erythrocytes, J. Clin. Invest. 67 (1981), 531-539.
8. J.L. Cracowski, C. Marpeau, P.H. Carpentier, B. Imbert, M. Hunt, F. Stanke-Labesque and G. Bessard, Enhanced in vivo lipid peroxidation in scleroderma spectrum disorders, Arthritis Rheum. 44 (5) (2001), 1143-1148.
9. J.L. Cracowski, P.H. Carpentier, B. Imbert, S. Cachot, F. Stanke-Labesque, J. Bessard and G. Bessard, Increased urinary F2-isoprostanes in systemic sclerosis, but not in primary Raynaud's phenomenon: effect of cold exposure, Arthritis Rheum. 46(5) (2002), 1319-1323.
10. M.A. Creager, K.M. Pariser, E.M. Winston, H.M. Rasmussen, K.B. Miller and J.D. Coffman, Nifedipine-induced fingertip vasodilation in patients with Raynaud's phenomenon, Am. Heart J. 108(2) (1984), 370-373.
11. M. Detraglia, F.B. Cook, D.M. Stasiw and L.C. Cerny, Erythrocyte fragility in aging, Biochim. Biophys. Acta 345 (1974), 213-219.
12. E. Ernst, E.F. Lohmaier, M. Meurer and J. Gerstmeier, Decreased blood fluidity in progressive systemic scleroderma, Z. Rheumatol. 49(3) (1990), 155-159.
13. ++content in exercising ischaemic limb, Clin. Hemorheol. 12 (1992), 1527-1534.
14. E. Genazzani and M. Doni, Drugs acting on erythrocytes, Ric. Clin. Lab. 13(Suppl. 3) (1983), 257-262.
15. T. Gori and S. Forconi, The role of reactive free radicals in ischemic preconditioning - clinical and evolutionary implications, Clin. Hemorheol. Microcirc. 33 (2005), 19-28.
16. N. Gurbuz, O. Yalcin, T.A. Aksu and O.K. Baskurt, The relationship between the enzyme activity, lipid peroxidation and red blood cells deformability in hemizygous and heterozygous glucose-6-phosphate dehydrogenase deficientindividuals, Clin. Hemorheol. Microcirc. 31 (2004), 235-342.
17. Y. Huang, D. Liu and S. Sun, Mechanism of free radical on the molecular fluidity and chemical structure of red cell membrane damage, Clin. Hemorheol. 23 (2000), 287-290.
18. Y. Itoh, R. Takaoka, M. Ohira, T. Abe, N. Tanahashi and N. Suzuki, Reactive oxygen species generated by mitochondrial injury in human brain microvessel endothelial cells, Clin. Hemorheol. Microcirc. 34 (2006), 163-168.
19. D. Kamp, T. Sieberg and C.W. Haest, Inhibition and stimulation of phospholipid scrambling activity. Consequences for lipid asymmetry, echinocytosis, and microvesiculation of erythrocytes, Biochemistry 40(31) (2001), 9438-9446.
20. W. Koenig and E. Ernst, The effects of calcium channel blockers on blood fluidity, J. Cardiovasc. Pharmacol. 16(Suppl. 6) (1990), 40-44.
21. I.B. Kovacs, S.O. Sowemimo-Coker, J.D. Kirby and P. Turner, Altered behaviour of erythrocytes in scleroderma, Clin. Sci. (Lond.) 65(5) (1983), 515-519.
22. H. Larsson, S.U. Persson and P. Hedner, Changes in the functional state of the erythrocyte membrane: significance for red cell filterability and blood viscosity, Scand. J. Clin. Lab. Invest. 50 (1990), 177-181.
23. M. Lauterbach, G. Horstick, N. Plum, A. Heimann, D. Becker, L.S. Weilemann, T. Munzel and O. Kempski, Prolonged recirculation is required to detect secondary metabolic and hemodynamic deterioration after superior mesenteric artery occlusion, Clin. Hemorheol. Microcirc. 32 (2005), 1-12.
24. C. Leighton, Drug treatment of scleroderma, Drugs 61(3) (2001), 419-427.
25. S. Lin, E. Yang and W.H. Huestis, Relationship of phospholipid distribution to shape change in calcium-crenated and recovered human erythrocytes, Biochemistry 33(23) (1994), 7337-7344.
26. X. Liu, W. Qin and D. Yin, Biochemical relevance between oxidative/carbonyl stress and elevated viscosity of erythrocyte suspensions, Clin. Hemorheol. Microcirc. 31 (2004), 149-156.
27. D.F. Murrell, A radical proposal for the pathogenesis of scleroderma, J. Am. Acad. Dermatol. 28(1) (1993), 78-85.
28. ++ influx and cAMP-mediated signaling pathways, Am. J. Physiol. 273 (1997), C1828-1834.
29. P. Ostojic, N. Damjanov, S. Pavlov-Dolijanovic and G. Radunovic, Peripheral vasculopathy in patients with systemic sclerosis: difference in limited and diffuse subset of disease, Clin. Hemorheol. Microcirc. 31 (2004), 281-285.
30. H.L. Reid, J.A. Dormandy, A.J. Locks and T.L. Dormandy, Impaired red cell deformability in peripheral vascular disease, Lancet 1 (1976), 666-668.
31. R.J. Rodeheffer, J.A. Rommer and F. Wigly, Controlled double-blind trial of nifedipine in the treatment of Raynaud's phenomenon, N. Engl. J. Med. 308 (1980), 880-883.
32. L.M. Ruiz Martin, J. Rodriguez Moreno and X. Juanola Roura, Fenómeno de Raynaud, Piel 3 (1988), 309-317.
33. M.H. Rustin, I.B. Kovacs, S.O. Sowemino-Coker, P.J. Maddison and J.D. Kirby, Differences in red cell behaviour between patients with Raynaud's phenomenon and sclerosis and patients with Raynaud's disease, Br. J. Dermatol. 113(3) (1985), 265.
34. A.N. Sapadin and R. Fleischmajer, Treatment of scleroderma, Arch. Dermatol. 138(1) (2002), 99-105.
35. S. Mitaku and S. Aruga, Effect of calcium ion on the mechanical properties of lipid bilayer membrane, Biorheology 19 (1982), 185-196.
36. G. Simonini, M.M. Cerinic, S. Generini, M. Zoppi, M. Anichini, C. Cesaretti, A. Pignone, F. Falcini, T. Lotti and M. Cagnoni, Oxidative stress in systemic sclerosis, Mol. Cell Biochem. 196(1-2) (1999), 85-91.
37. C.R. Smith and R.J. Rodeheffer, Raynaud's phenomenon: pathophysiologic features and treatment with calcium-channel blockers, Am. J. Cardiol. 55(3) (1985), 154B-157B.
38. R. Solans, C.Motta and R. Solá, Abnormalities of erythrocyte membrane fluidity, lipid composition, and lipid peroxidation in systemic sclerosis, Arthritis and Rheumatism 43(4) (2000), 894-900.
39. S.O. Sowemimo-Coker, I.B. Kovacs, J.D. Kirby and P. Turner, Effects of verapamil on calcium-induced rigidity and on filterability of red blood cells from healthy volunteers and patients with progressive systemic sclerosis, Br. J. Clin. Pharmacol. 19(6) (1985), 731-737.
40. M.A. Srour, Y.Y. Bilto, M. Juma and M.R. Irhimeh, Exposure of human erythrocytes to oxygen radicals causes loss of deformability, increased osmotic fragility, lipid peroxidation and protein degradation, Clin. Hemorheol. 23 (2000), 13-21.
41. M.I. Spengler, M.J. Svetaz, M.B. Leroux, M.L. Leiva and H.M. Bottai, Association between capillaroscopy, haemorheological variables and plasma proteins in patients bearing Raynaud's phenomenon, Clin. Hemorheol. Microcirc. 30 (2004), 17-24.
42. C.M. Stein, S.B. Tanner, J.A. Awad, L.J. Roberts and J.D. Morrow, Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma, Arthritis Rheum. 39 (1996), 1146-1150.
43. A.E. Thompson, B. Shea, V. Welch, D. Fenlon and J.E. Pope, Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis, Arthritis Rheum. 44(8) (2001), 1841-1847.
44. K. Tsuda, S. Tsuda, Y. Minatogawa, H. Shima, H. Yoshikawa, I. Nishio, R. Kido and Y. Masuyama, Effects of calcium antagonists on membrane fluidity in hypertension - an electron spin resonance study, Am. J. Hypertens. 1 (1988), 283-286.
45. V. Turchetti, F. Leoncini, C. De Matteis, L. Trabalzini, M. Guerrini and S. Forconi, Evaluation of erythrocyte morphology as deformability index in patients suffering from vascular diseases, with or without diabetes mellitus: correlation with blood viscosity and intra-erythrocytic calcium, Clin. Hemorheol. 18 (1998), 141-149.
46. A. Vaya, M. Simo, M. Santaolaria, J. Todoli and J. Aznar, Red blood cell deformability in iron deficiency anaemia, Clin. Hemorheol. Microcirc. 33 (2005), 75-80.
47. M. Vetrugno, G. Cicco, F. Cantatore, L. Arnese, N. Delle Noci and C. Sborgia, Red blood cell deformability, aggregability and cytosolic calcium concentration in normal tension glaucoma, Clin. Hemorheol. Microcirc. 31 (2004), 295-302.
48. H. Watanabe, A. Kobayashi, T. Yamamoto, S. Suzuki, H. Hayashi and N. Yamazaki, Alterations of human erythrocyte membrane fluidity by oxygen-derived free radicals and calcium, Free Radic. Biol. Med. 8(6) (1990), 507-514.
49. R.I. Weed, P.L. LaCelle and E.W. Merrill, Metabolic dependence of red cell deformability, J. Clin. Invest. 48(5) (1969), 795-809.
50. F.M. Wigley, R.A. Wise and R. Malamet, Nicardipine in the treatment of Raynaud's phenomenon, Arthritis Rheum. 30(1987), 281-286.
51. E.L. Winston, K.M. Pariser, K.B. Miller, D.N. Salem and M.A. Creager, Nifedipine as a therapeutic modality for Raynaud's phenomenon, Arthritis Rheum. 26(10) (1983), 1177-1180.
52. 2+-induced scrambling of phosphatidylserine, Mol. Membr. Biol. 20(1) (2003), 83-91.
53. 2+ sensitivity of phospholipid scrambling in human red cell ghosts, Cell Calcium 25(4) (1999), 313-320.
54. M.B. Yerer, H. Yapislar, S. Aydogan, O. Yalcin and O. Baskurt, Lipid peroxidation and deformability of red blood cells in experimental sepsis in rats: The protective effects of melatonin, Clin. Hemorheol. Microcirc. 30 (2004), 77-82.
55. S. Zeni and F. Ingegnoli, Raynaud's phenomenon, Reumatismo 56(2) (2004), 77-81.